Results 1 to 10 of about 7,292 (203)
Dermatology and Therapy, 2023 Introduction This study assessed the levels of compliance to topical minoxidil (TM) among male and female patients with androgenetic alopecia (AGA) and analyzed the factors associated with minoxidil discontinuation.
Shadi Zari
exaly +2 more sources
Minoxidil ameliorates myelodysplastic syndrome by targeting Wnt4 while sparing normal hematopoiesis [PDF]
Cell Communication and SignalingBackground Hematopoietic stem cells (HSCs) maintain blood production via tightly regulated differentiation. Disruptions at this level can lead to myelodysplastic syndromes (MDS), characterized by ineffective hematopoiesis and marrow failure.
Xiaoling Shi +7 more
doaj +2 more sources
Using a Natural Clay Mineral as an Active Drug Carrier to Promote Hair Growth [PDF]
PharmaceuticalsBackground: Topical minoxidil remains the only FDA-approved treatment for hair loss, yet its clinical efficacy is compromised by organic-solvent-induced scalp irritation and poor patient adherence. This study aimed to evaluate natural illite as a carrier
Zhiqing Liu +9 more
doaj +2 more sources
Pharmaceutics, 2022 The purpose of this study was to evaluate mechanisms behind the intestinal permeability of minoxidil, with special emphasis on paracellular transport, and elucidate the suitability of minoxidil to be a reference drug for Biopharmaceutics Classification ...
Milica Markovic +6 more
doaj +1 more source
Medicine in Drug Discovery, 2020 Aims: Minoxidil is a hair growth drug for treating androgenetic alopecia. Although minoxidil is generally administered as a topical formulation, this prodrug must be converted to its active form (minoxidil sulfate) by sulfotransferase in hair follicle ...
Mio Ichida +4 more
doaj +1 more source
Could Topical Minoxidil Cause Non-Arteritic Anterior Ischemic Optic Neuropathy? [PDF]
Journal of Clinical and Diagnostic Research, 2016 Minoxidil hair formulation is commonly used for the treatment of male or female androgenic alopecia. Minoxidil is a Health Canada and US FDA-approved medication for hair loss in men and women. The drug is marketed as 2% and 5% topical solutions.
Habibullah Aktas +3 more
doaj +1 more source
Aktualʹnì Pitannâ Farmacevtičnoï ì Medičnoï Nauki ta Praktiki, 2023 The treatment and prevention of hair loss have been a serious aesthetic problem for the population for a long time due to the widespread occurrence of the condition and its undesirable medical and social consequences.
V. V. Hladyshev +6 more
doaj +1 more source
Successful management of suspected minoxidil toxicosis in a cat following accidental dermal exposure
Veterinární Medicína, 2022 Minoxidil was originally introduced as a potent vasodilator, but is now widely used as a topical treatment for human alopecia. A 4-year-old neutered male Norwegian Forest cat presented with a 2-day history of anorexia, lethargy, and dyspnoea.
Song JH, Kim SY, Moon JH, Jung DI
doaj +1 more source
Minoxidil and Dexamethasone Eluting Nanofiber Dressing for Cutaneous Wound Healing in Rat [PDF]
Pharmaceutical Sciences, 2023 Background: Minoxidil is an antihypertensive agent and vasodilator which may help to promote local blood flow thus hastening the closure of excisional skin wounds. Corticosteroids may down-regulate wound healing.
Saber khozan +4 more
doaj +1 more source
Pharmaceutics, 2018 In this work, we examined enhanced skin delivery of minoxidil applied in nanoemulsions incorporating skin penetration enhancers. Aliquots of fully characterized oil-in-water nanoemulsions (1 mL), containing minoxidil (2%) and the skin penetration ...
Eman Abd +3 more
doaj +1 more source